Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vinylglycine is a non-proteinogenic amino acid derivative characterized by the presence of a vinyl group attached to the alpha-carbon of glycine. It exists as both D and L enantiomers, with L-vinylglycine being more commonly referenced in biochemical contexts. Vinylglycine acts as an irreversible inhibitor of aspartate aminotransferase, interfering with transamination reactions in amino acid metabolism. It also inhibits EC 4.4.1.14 (1‑aminocyclopropane‑1‑carboxylate synthase), impacting ethylene biosynthesis pathways in plants and certain metabolic processes in fungi[1][2][5][6]. Its unique structure makes it useful for research into enzyme mechanisms, peptide synthesis, and as an intermediate for developing novel pharmaceuticals or agrochemicals[3][7]. Vinylglycine is not approved for clinical use and is primarily used experimentally.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on vinylglycine.